The brokerage expects Dr Lal to outperform industry growth and register revenue, EBITDA and PAT growth at CAGRs of 11.9 per cent, 16.1 per cent and 21.8 per cent, respectively, over FY20-FY22E.from Markets-Economic Times https://ift.tt/3g6PRhi
via
The brokerage expects Dr Lal to outperform industry growth and register revenue, EBITDA and PAT growth at CAGRs of 11.9 per cent, 16.1 per cent and 21.8 per cent, respectively, over FY20-FY22E.from Markets-Economic Times https://ift.tt/3g6PRhi
via
No comments:
Post a Comment